{"ticker": {"uuid": "d35c590d-0934-414b-8dd9-361ee4d8852a", "symbol": "AUPH", "name": "Aurinia Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Understanding Momentum Shifts in (AUPH)", "summary": "This article analyzes Aurinia Pharmaceuticals Inc (AUPH), indicating a strong overweight bias across all time horizons due to strong sentiment. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies with specific entry, target, a", "url": "https://news.stocktradersdaily.com/news_release/89/Understanding_Momentum_Shifts_in_AUPH_061926080801_1781914081.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T20:08:00", "published_display": "19 Jun 2026 20:08", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How New LUPKYNIS Renal Outcomes Data Could Impact Aurinia Pharmaceuticals (AUPH) Investors", "summary": "Aurinia Pharmaceuticals recently announced new AURORA 1 Phase 3 analysis at the EULAR 2026 Congress, showing LUPKYNIS significantly reduced renal-related events or death in lupus nephritis patients. This data strengthens the clinical evidence for the drug but does not eliminate r", "url": "https://www.sahmcapital.com/news/content/how-new-lupkynis-renal-outcomes-data-could-impact-aurinia-pharmaceuticals-auph-investors-2026-06-19", "source_name": "Sahm", "published_at": "2026-06-19T04:41:17", "published_display": "19 Jun 2026 04:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Aurinia Pharmaceuticals Inc's (AUPH) shareholder structure, listing major shareholders and institutional holdings. It highlights top individual shareholders like Tang Capital Management, LLC and BlackRock, along with a classification ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-auph/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T08:38:51", "published_display": "18 Jun 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Aurinia Pharmaceuticals Inc (AUPH), detailing regional contributions. It shows that the United States accounts for 93.21% of its revenue, totaling $263.84 million, while Japan contributes 6.79% with $19.21 million. Information on reve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-auph/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:01", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Aurinia Pharmaceuticals Inc (AUPH) has an earnings forecast score of 7.43, ranking 291 out of 388 in its industry. Analysts have set an average price target of $17.00 for AUPH, with most supporting a \"Buy\" trend. The company's expected revenue for the next quarter is $79.70 milli", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-auph/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:10:01", "published_display": "17 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals (AUPH) Stock Could Be 4.6% Undervalued After New LUPKYNIS Phase 3 Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T08:28:54+00:00", "published_display": "17 Jun 2026 08:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxOMENrNGt6UDlBamgwMmZFUmJzMjRwZUo2YUhjd3ZmM0hHTXhKY3dtZFFkWVFPR2xjRHdlb1VfbDVucHhjaWhfU1cxNnVnUU5PZjZnZ3JLOVRkX28xbkZ6RWdDQ09YalVNVzZzR3RZWUtmNUh4Y0hJQXQ1V0loRkJaUVBCYl9SN0w1cjlSYi02N0FpcUNRcVVFQk1yal93ZWJwOWVwa1FYa0hFdEUtY1pZQzZUNjhRbjlDVmdxNnczZzB2Vk5naG9rRU1zUi01NHVoOWNNc3AySlJxRlFVZ1JxNDNqcmJrUU9lbVZBaTZOVUtHVEVzdXQwUVNCNDR6SEl6YXlDa1ZQTFk1d0pvaG1Da1JR?oc=5", "source_name": "ChartMill", "published_at": "2026-06-16T09:10:35+00:00", "published_display": "16 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals and Four More Stocks See Activist Action", "summary": "This article reports on recent activist actions disclosed to the SEC, specifically focusing on Aurinia Pharmaceuticals and four other companies. The information is derived from 13D filings, which are required when an entity acquires more than 5% ownership in a company's securitie", "url": "https://www.barrons.com/articles/activists-13ds-aurinia-pharmaceuticals-dell-victorias-secret-valaris-univertal-technical-institute-7ffc01fc", "source_name": "Barron's", "published_at": "2026-06-13T02:40:16", "published_display": "13 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSVBDS29OM0lWcG56d1NXNmxlU1ZIdnpyWFZENy1kYUI2S2lTZnJvTDhEVFFIdWRKOUFkR1lIUFctVGZCNVhuVU5kdUVyX0xHM0xnWkRsbzFiOGtBbHFCUHNBR0FSOHUwaHd2OTZSZmJMVWVLcFVhYjd2YldnakhWMFFTTzZDQ0ZFdUV1cFVKV3hHWU5DWWx6LTd0aWdxQ0VRTmNmU1ZHOA?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following New LUPKYNIS Kidney Outcomes Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxOWmdVX0JiWWdRNzhLemhRQ2RKT1ROME9HR0RUaDFGdDg0Qkk0OXV0aHJZbW1GcHBKS1Q4cThiU2o3enNLQzZOMUpqYjU3QkhJdFljbEczUllqV0VGX0NTcFpReG9JcUloZU9kVExwcjdiRWo3bldibFFzX29YUFdxb0p4eTZxLUF2eHFsbndrRzhkOXJtWGcyUHBvd0cwemtBb3o3QUFWbHNIV2d1aU9GeDNZTEdPUHdnanZjYms3X2c2Z3ZrbGJ6Qmtsc0FkXzVFQkR6dGVRelpLWkdJOGY1OHpvcHBha0JpbEtKOXpDc9IB9AFBVV95cUxQYVZjTHFZb2gzTGNRZEFnZF9zS0lXXzJjRmEzdDdXT0NkZUVsZDNoUUIwOHhNdUNLbnVvRW1tVTEzN2hwSEJaVzhLVV9sOXlmWEl3bkRYeFhSMUxqZGc1YmJYaFBFQVlIanFya01kQU5RVU5kcnZ3Q2ZZOGhjZ0U0bFctLVp1MjJfbFpNU0U5aDJvNlhvSmE3NUxtQ1JsblRVcGxuazJzZXNDTnhpMHlkUjlYVXRZM2xUOXhCR3ZJYTdqVkYtaGlXSkYxcF9FT1pKUEVZR3BvQXRkNTlIRlMtajJMY0JlYjZFYXRFWnhPVTJjU1dv?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T08:33:07+00:00", "published_display": "10 Jun 2026 08:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia (AUPH) director Jeffrey Bailey granted 23,931 stock options at $15.67", "summary": "Aurinia Pharmaceuticals Inc. director Jeffrey Allen Bailey was granted 23,931 stock options with an exercise price of $15.67 per share. These options are part of his compensation, will vest one year from the grant date, and are set to expire on June 4, 2036. This transaction refl", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-f268386fd5eb.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:10:26", "published_display": "08 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036", "summary": "Aurinia Pharmaceuticals director Kathleen Goetz was granted 23,931 Director Stock Options on June 4, 2026, as compensation. These options have an exercise price of $15.67 per share and will expire on June 4, 2036, vesting one year from the grant date. Following this award, her di", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-170e57b99845.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:10:26", "published_display": "08 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant", "summary": "Aurinia Pharmaceuticals Inc. (AUPH) director Tina Susan Nova was granted 23,931 stock options as compensation, which are exercisable at $15.67 per share and will vest one year from the grant date of June 4, 2026. The options are set to expire on June 4, 2036. This transaction is ", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-c6eb05895c51.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:10:26", "published_display": "08 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options", "summary": "Aurinia Pharmaceuticals Inc. director Craig A. Johnson was granted 23,931 stock options as part of his compensation, with an exercise price of $15.67 per share. These options are set to vest one year from the grant date and will expire on June 4, 2036. The Form 4 filing indicates", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-a295bae126e4.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:10:26", "published_display": "08 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Long Term Shareholder Returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million", "summary": "Aurinia Pharmaceuticals' (AUPH) CEO, Kevin Tang, indirectly purchased 814,606 common shares across several transactions between May 29, 2026, and June 2, 2026, totaling approximately $12.5 million. This significant acquisition, representing 6.66% of his total holdings, occurred j", "url": "https://www.fool.com/coverage/filings/2026/06/07/ceo-buys-auph-815k-shares-for-125-million/", "source_name": "The Motley Fool", "published_at": "2026-06-07T13:09:01", "published_display": "07 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sales, option exercise at AUPH (NASDAQ: AUPH) reported", "summary": "A recently filed Form 144 for Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) details proposed and recent transactions involving option exercises and sales of common stock. The filing indicates a planned sale of 9,593 shares connected to an option exercise dated June 5, 2026, and als", "url": "https://www.stocktitan.net/sec-filings/AUPH/144-aurinia-pharmaceuticals-inc-sec-filing-4e7068d357ef.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:10:17", "published_display": "05 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Health Care Stocks Whale Activity In Today's Session", "summary": "This article identifies significant \"whale activity\" in the options market for ten healthcare stocks, including Aurinia Pharmaceuticals (AUPH), UnitedHealth Group (UNH), and Eli Lilly and Co (LLY). It details specific bullish or bearish options trades, their expiration dates, str", "url": "https://www.benzinga.com/insights/options/26/06/53037272/10-health-care-stocks-whale-activity-in-todays-session", "source_name": "Benzinga", "published_at": "2026-06-05T17:10:17", "published_display": "05 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tang group discloses 10% Aurinia (AUPH) stake plus $15 put options", "summary": "Tang Capital Management and affiliated entities have amended their Schedule 13D filing, revealing a beneficial ownership of 10.0% in Aurinia Pharmaceuticals Inc., totaling 13,044,106 common shares as of June 3, 2026. The filing also discloses that the group holds put option contr", "url": "https://www.stocktitan.net/sec-filings/AUPH/schedule-13d-a-aurinia-pharmaceuticals-inc-amended-major-shareholder--fd78ca986430.html", "source_name": "Stock Titan", "published_at": "2026-06-04T23:08:43", "published_display": "04 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong shareholder support for Aurinia (NASDAQ: AUPH) board, auditor and say-on-pay", "summary": "Aurinia Pharmaceuticals Inc. shareholders demonstrated strong support for the company's leadership and compensation plan at its 2026 annual general meeting. All five director nominees were elected with significant majorities, ranging from 86.50% to 96.59% of votes. Additionally, ", "url": "https://www.stocktitan.net/sec-filings/AUPH/8-k-aurinia-pharmaceuticals-inc-reports-material-event-a3e53a2b6518.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:39:41", "published_display": "04 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUPH: 25,000-share option exercise filed; Keenan sold 25,000 on 06/02/2026", "summary": "A Form 144 filing for Aurinia Pharmaceuticals Inc. (AUPH) indicates a 25,000-share option exercise with a proposed sale on June 4, 2026, settled by cash. The filing also notes a previous sale by Gregory Keenan of 25,000 shares on June 2, 2026, for $54,100,000. These transactions ", "url": "https://www.stocktitan.net/sec-filings/AUPH/144-aurinia-pharmaceuticals-inc-sec-filing-28de1409b136.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:39:41", "published_display": "04 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow (NASDAQ:AUPH)", "summary": "Aurinia Pharmaceuticals (AUPH) is poised for profitable growth, buoyed by strong financial results from Lupkynis and strategic pipeline expansion through the Kezar Life Sciences acquisition. The company reported impressive 1Q26 figures, including double-digit revenue and net inco", "url": "https://seekingalpha.com/article/4911916-aurinia-cash-generating-today-pipeline-driven-tomorrow", "source_name": "Seeking Alpha", "published_at": "2026-06-04T12:39:41", "published_display": "04 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock", "summary": "A 10% shareholder of Aurinia Pharmaceuticals (AUPH.US) recently purchased 2,367,314 shares of common stock for a total of US$12.46 million. This transaction occurred at an average price of US$5.26 per share. Following this purchase, the shareholder now directly owns 20,449,602 sh", "url": "https://www.moomoo.com/news/post/70963167/aurinia-pharmaceuticals-auphus-10-shareholder-buys-us-12-46-million", "source_name": "Moomoo", "published_at": "2026-06-04T09:39:13", "published_display": "04 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Insider Bought Shares Worth $12,455,227, According to a Recent SEC Filing", "summary": "This article reports on a significant insider purchase of Aurinia Pharmaceuticals shares. An insider acquired shares valued at $12,455,227, as disclosed in a recent SEC filing. This transaction could indicate insider confidence in the company's future prospects.", "url": "https://www.moomoo.com/news/post/70978343/aurinia-pharmaceuticals-insider-bought-shares-worth-12455227-according-to-a", "source_name": "Moomoo", "published_at": "2026-06-04T02:39:41", "published_display": "04 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.", "summary": "TANG CAPITAL MANAGEMENT, LLC has filed an early warning report concerning Aurinia Pharmaceuticals Inc. (AUPH). Quantisnow, a market data and news platform, provided this update, alerting its Plus members shortly after publication. The platform aggregates real-time information suc", "url": "https://www.quantisnow.com/insight/tang-capital-management-llc-files-early-warning-report-respecting-aurinia-6585548", "source_name": "Quantisnow", "published_at": "2026-06-03T23:10:26", "published_display": "03 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy", "summary": "Aurinia Pharmaceuticals' CEO, Kevin Tang, recently made a substantial insider purchase of 814,606 shares, totaling $12.46 million. This transaction signals insider confidence in the company, whose shares saw a 2.47% increase on Wednesday morning. The company demonstrated strong f", "url": "https://www.benzinga.com/insights/news/26/06/52974540/chief-executive-officer-of-aurinia-pharmaceuticals-makes-12-46m-buy", "source_name": "Benzinga", "published_at": "2026-06-03T15:10:27", "published_display": "03 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals stock (CA05156H1070): shares steady as Nasdaq-listed biotech advances myasth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQS2w1a1llS1lpQ0R2dVhSdTlYcGN2NzlYcG9vSEVrdGZDMW1JcUFGSTZiTzF2MTBPV1Nhcl9VOVdzNE90R3NZaThlYmVHUkc3LWd0UHdpLWtVdndvWTVaWnNyQXlFaENyc3hMcDAtb1Q4VTg3aG9mZDhTSFl3Q0J3emtfNmprWW9qWHlsTGprMWZMLWFQZE82T2c2Qmd6VHI2eDFVWk81eEFaY3lXWlljcjFGZzZQNWFVRUE?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options", "summary": "Entities linked to Aurinia Pharmaceuticals (AUPH) CEO Kevin Tang significantly increased their stake in the company by purchasing 814,606 common shares at around $15 per share. These funds now indirectly hold 13,044,106 shares. Additionally, Tang-affiliated funds sold 10,000 shor", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-7b1285a468b2.html", "source_name": "Stock Titan", "published_at": "2026-06-03T01:33:35", "published_display": "03 Jun 2026 01:33", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25,000-Share Sale Notice for AUPH (NASDAQ: AUPH)", "summary": "Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has filed a Form 144 notice for the proposed sale of 25,000 shares of common stock on June 2, 2026. This sale is tied to the exercise of options under a registered plan and will be an issuer-directed sale with cash proceeds. The filing ", "url": "https://www.stocktitan.net/sec-filings/AUPH/144-aurinia-pharmaceuticals-inc-sec-filing-590370bdd580.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:13:15", "published_display": "02 Jun 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals stock (CA05156H1070): shares steady on Nasdaq after Q1 2026 earnings beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUnJlUXNZQW55bzV1X3FaaEZkNEhpRUNocFFwY1lHRnIwUml6RnAwNGpNNEVJRVhpS2EwME84ZUliU1lrc2dXeFg2a2hGaWhfX1RJeWE4YTkwWkV2cWJkbjhGZEQtZlFoRERiV2RObF9PUTN4WmEzTjFvdFZoWHc0dGdGQ0RzNnBNaFlpQUhSbmw2cEc4TmhDaFJabDJ3bU1QS29Ta19lWnRkdGJyU09RanNYa28yQnRzeGFDQzlWc3hLM2c?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-01T19:32:33+00:00", "published_display": "01 Jun 2026 19:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in AUPH Response", "summary": "This article analyzes Aurinia Pharmaceuticals Inc (AUPH) using AI models, identifying divergent sentiment across different time horizons. It provides specific trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with entry zones, targets, and stop losses. The ", "url": "https://news.stocktradersdaily.com/news_release/101/Discipline_and_Rules-Based_Execution_in_AUPH_Response_052826053002_1780003802.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-28T17:10:45", "published_display": "28 May 2026 17:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments", "summary": "Aurinia Pharmaceuticals (AUPH) has maintained an analyst consensus target of $17.00, supported by updated model inputs and recent sector deal activity, though some analysts express caution regarding company-specific execution risks. The company recently appointed new executives a", "url": "https://simplywall.st/narratives/u6qzqcmm-auph-future-opportunities-will-depend-on-pipeline-clarity-and-risk-developments?bpId=4200549&link_type=cta_ai_narrative", "source_name": "Simply Wall Street", "published_at": "2026-05-27T20:09:10", "published_display": "27 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO", "summary": "Aurinia Pharmaceuticals (AUPH) has granted its Chief Financial Officer, Michael S. Hearne, 116,144 performance stock units (PSUs) and 70,230 employee stock options. The PSUs are performance-based, vesting in tranches upon the company's shares reaching specific target prices and t", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-7409ad983245.html", "source_name": "Stock Titan", "published_at": "2026-05-21T03:39:03", "published_display": "21 May 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options", "summary": "Aurinia Pharmaceuticals Inc.'s Chief Operating Officer, Ryan Cole, was granted 116,144 performance stock units (PSUs) and 70,230 stock options. These equity awards are compensation-related, with the PSUs vesting based on share-price targets and time-based conditions, and the stoc", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-b5bce3850f27.html", "source_name": "Stock Titan", "published_at": "2026-05-20T21:09:21", "published_display": "20 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQemQ4eGdLVEFncHE0ODJmSmRLWnA5dzlNMVJBZFBvc3dnNklldC1ob1RwOE9zaE1OV3JnQzJBZ0hoZVZjTmlMVTdqaDVZT0lzMG0yM21jVnFWZGNXNzBYUHduZ1VLQ2JkTXQ0VEQ4Mk9mOGRDcVM1cVFaazZfZjRWaGgySnpkVXBKZXFlOWdyeDRLcXBmSXpWWjNOUjc5UlZHT2o2RzJhUGUwbFJyY3lBQkw1OWk0bk90UEFEdmhLaHkzT05zamQzdVNkRFVHVWtMVlg1X0EtTFZPbUs5dG5OU1lKaHAzZDlub3g3Y2lR0gHzAUFVX3lxTFBWQ0hBdmVwN2VZbk5rTWM4R29tYkE4UlNBVlJ2czJWZHByb0JLcXd6c1FiUEg4aHlIaW9zSmF0NmxURWRDY3VmNktUNFhPRVhqVVlFdkZiMXlRNEluUXdJWDlQS3BFNE1MaDBlMHV0NG83MGl2VE1QTkk0aHFFLU9wU29UcmtPaGdaalhQNG5hbURsb2F3dEM5TDlGdnBkQ0lzV0NCUGkySFFMaEM1VTNFNVk1dUZhSlZJT0V4a2JVSHJhZXBES0UwXzY1ZWU1Unl1dHllOGdvWnp6RU5QTlRjYVg1aHJ2S2E2dktZZkF3d2NjRQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOMktqVFJ4TFZzV2NDeERPNWZwMkxycmhaamcxT3oyRWp4SUEwbmtqRkZCMU9lN3ZDajE4RXpfS0NuZzc0RFNPYms1OGhGM0FaaktVUzdSUjZUbEJValF3VlNCN2x1SDk1bFlEcDZNQnFBek1TM3Q0SmhPMkVFQnprLVNTREMtTkhvN3daQ0F2ZnUzY3k0ekhLNU93Nk1nMkg3cjRKVFdWcWZVWFlH?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aurinia Pharmaceuticals stock (CA05156H1070): Announces $6.955 Cash Acquisition of Kezar Life Scienc", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNSEFGSDh0cjVVWF91MnhSNVBXSjlPRVJtSWM4aVlld0gtX0ZtUS1Cbjc4RGxyaXQtQklOcVdVSXpOaWhSRk00ajZWRWRmSWQ2NXNJbWZIMENqZkJnQ25HaWwzMnlDbVE2U0ZSbm5nX1IyUUV3Rlp6U1A4dG01b3pHa0g2LUtCQ0VhQkRieTFvQVJxRWRqOE4yWkdoMVY5T3dwODVob1UtNVVOLTZueGJEcFZTTVk1aUI3VjNXWFB5Zw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kezar Life Sciences acquired by Aurinia Pharma U.S.; Nasdaq delisting follows", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPS0stcVVmbjh0UnJqbVp5X2tSQmJRd2gtSVh2cVNZMmk4amRYbkFNQTY0XzdBMkxiMktLMDBuUnpnU3R3MHBVVUVWcnkzNW5jbnNsVUVDeXZ0RDhDOTRYWm9WTjBVR2hNWjJOT0FkS1ZsYVBUVUN5aGlPLUQxQnVjSFRVTHFrd21Pa2ZmOHRPOXN0QWJJMDE1SkJma2g4aGFwbDBOQTR1OERwT0Fvd25pbnduc2lmaWpPNG55ZTk5bDBDZVpoMmJXNU5R?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "500,503 AUPH shares listed for resale by Morgan Stanley (NASDAQ: AUPH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOOGVqSGpxU2ZUTlZwelRoUWV3MURRYkZkWlJ5M1d3dDlZbHVGdzVzRnNHb3hQYkxLNmJ2WUhGNDAwREluWEZqb0h6YkNXWmxSNjhJZmdPX0NhMXFhWk5ha09IZzhUWEUyQ0hFSWF1TWVNaEpHVjBiazVsYnk4cjM4MFhHYzAtOFdTdmtmNkZCTUczTm9TQWJvVnh5bGdHWVhFZy1vekl1RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOc0RxM2VTc0ZtRHRUWnM2OGMwTWE4X1BUaFYtXzlzNEFtNGt3eklfUllQWmU4WlJyQXV0UTdobWZVZEtKcGY4b3FDWVZNZUVtZnBCZW5PSG1mUDdiSml4N0xHLVJsUnRPMEpoX0t4WEhPczlMeFdMN3NFVHZRNjdXRmdwVFByMTlqZzYyZDlEYVhYcllXUFhvZTdXTlFEY2RxeE9EM0RNMUIxOFVpSEE?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Screens Strong on Minervini Trend Template and High Growth Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNdVRfRW9xNEFoN0Zhd0NoYkF6RnlVbk1SZ0VvcDBuSTR4YlBMajkxUWJjMnp2aXd3eUhRMEhvUjNxTjVKWV9zZEk0TFRjdkhNRlp1VER5a0lkLVNPMUhqc3lSR09GZjludnFtd29GYndmMWJQMGEtdG1wNmhTQmpDeEZ3MXk0LUYwZDNhSW9CLTYwbXM5M1Q2dW45R0RCWFdMTGw1Y1lYcE5zb213S3Fsdmh1NFFrLVk2RG5RU1JGRkFwdUhvX3RSYXZVOUFCeFkyVk92RVVLaDE4YXktLVl6aWZNaXNPTzVvTHVhZ3lCdw?oc=5", "source_name": "ChartMill", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUPH (Aurinia) beats Q4 2025 EPS estimates by 17.6 percent, yet shares dip 1 percent in today\u2019s session.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOaTgwQjV4aVo4YzZabmNzVFp0ZV9kUDIwQldjVDQzTVcwZG5xZzAwekVJS2g0dGk3NWRROXNrckI3a0ItS3dJRmt3V0d1c2lqQlFRcVNGaEhkblU3bVdQOGVEU1VsUHE3V042RHlSS25JQXAxOUUxYWRDbk5zelJaLUJHZVY1TFBSSDVoOHFmdHkzS0xVSUhyeWhwREFmSlo3c2NIQzZCejYyWVF3UWJxbEhQRXo3YnFPd2N3a1lLTWFockpaYmJveVh1dHQxdURBNXducEc4UQ?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Aurinia Pharmaceuticals (AUPH) Pricing Reflect Long Term Value After 71% One Year Gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPMU04ellOeF9ZSWkwdVdwZEd5UTZwNDZhY1gyQVFESkN5eVlWMld0MFJJbF85ZTJaQUs4SGxvcTB1UXJVLTYwekp1RzhSVDE5aEZBRHVUb1VHTzBUcG50aEI1TjFlblhXUkZNZnlKQmF5YklQa09nUnFURFhKY0M1UHNkSHFEaGs0Qjc5UDg1WDFFMUFq?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUPH Stock Gains On Aurinia Pharma\u2019s Q4 Beat, But 2026 Guidance Misses Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQdmlya3JJeHF0TE1oT29lcDVZZzlndC0wZ19hU3NLVGtQWndqd0NzQmsxSUlUQlU3MGZiWDE0Rmx5WFNJYlRVMjI0UC1VSklURFlvVjBTRDRkVXB6ZFBIWm1JTUlXb3hJckV2bDFVOVcwMEpTbG14OUVPc2FCRjA0eG0zZ1k3OGs3Tm9BVnpxWjRUdHhMV0tBeU9nY1pyTVE4SllHSGhCMUs2N1BPelVFQUl6Zk01WkVybGdDS1B3RmFwcUZmQVhybTFVUUR1NFU?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 47, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief \u2014 Retail Traders Cry \u2018Stock Manipulation\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNZ0JFZFBCVElKc0w2LTd2VWJuMXk4YmN2aVU1TDBHUUxIOUNYU0U1ZmJiQUF6TjRoRUZvRm02aVVQaGt5Ti1IOHBtWWtzNUZ1SGlfSGFpbXVzSFVUNmxwMVBTUG1yVGM3QlRKVk9IODZ4eGFCR1pPMjdhMHlmel90XzEtanItSU5rNEJLeU1mQzZrZ25pODN4UnBQTGY1TF9Ha1QyLXdCcFFSbFRBS3h1aGU0QXZKekFvRzc4MU9fVnZUcmFna0Q5a21xNDhyQ3R6X2ZJOHBXSVlxRmY2MlE?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With 54% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNY2t1R0VQMlRGMjRUWjR0cEktd1dTcGtjSGpUaVRMd292NzR0QmJqTTQyMXRDVDhUUWRmT2IzWDBUbjdPT0poWXI3cmllWG1LS0pTdlVGQ2FuWS03azlRRnpmM2UyMGRMaUFUZWptbm9CdWRFTk9leG85VzR4ckdtb2VMODFyaTBOT2pWWjUwTkJRa0sxeDVlSnBhWlQ?oc=5", "source_name": "Market source", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOVZ0MTZsNmg4eGN5d1dOdk84Tk54NlE0bzdFaWhVZHFiSWNvX1ZBY1JFWWJUREpXSFlYb2Q1S1VkYmQzdDVSRjdFZTZpTUpFdzFtelZwZk53bFhsSmhmNDlweWZkUVpvczNYQkpDR0RpQWFEQnVOVE1LU3dMLVl0a055ZDBQTTZUQ0tjOGs3T3hqXy1DdklBblFFdGhyMWFlMzg0LU1RMGY?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNeEtmMFI0aDZ3MS1STFpyZzVtZzlHWEhacF9IdEE4ZVZOOXlnbHBLSWV3WjVzRnA1MjVWQjFzRERIY29QaGdlVlVaOXBvT1lmbWlIZnd2d19qVXdmeGcwZlplWDJ4REZ2S3hUX0VfaVBsNlBQOW9KOUJteTZLbFljRC1VZmdDN2pUWExlanUyRjhuVEwtQ3AwWV84dDdHUXB1bVFvLXU1ZDJxMU5PTG9QMk9KWDNtdEZhSEM2aTI3Z2RiY2FJYWJZM0l2bHhHazRQcnJMX1hvVGFKUWQ4bi1qTGxNVHZZd1nSAewBQVVfeXFMTm1HOFFxSGR3TUhXTDAtQjFvN2VPMkI4dU1JWXYxMDVNYm5kX1ZLSFpwWmdWbl9aaW5FdEhZNnNYbmFNM1pXTVRxVUI0cFlhcmp0ME1MRFRxV2FadGtXZ0tSX0ZfTjZ0dEdYMEptU3hJUmtycEJ3TTdGV3NjRDllcmZBLXNUX2p2MDVEY21wQXExdkNUVWxrc0c4Rkg5NVlhY0hhWmVmQ0VhWFJDS2NGbE9GT0IyYUZRckRJblRMTkxoN1RkaDBTaVN6T2tNbC1IQUlubHc4bjkzekNMWGNtZjRpd3hQSDFTYlRUZUk?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-08T08:00:00+00:00", "published_display": "08 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Understanding Momentum Shifts in (AUPH)", "summary": "This article analyzes Aurinia Pharmaceuticals Inc (AUPH), indicating a strong overweight bias across all time horizons due to strong sentiment. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies with specific entry, target, a", "url": "https://news.stocktradersdaily.com/news_release/89/Understanding_Momentum_Shifts_in_AUPH_061926080801_1781914081.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T20:08:00", "published_display": "19 Jun 2026 20:08", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How New LUPKYNIS Renal Outcomes Data Could Impact Aurinia Pharmaceuticals (AUPH) Investors", "summary": "Aurinia Pharmaceuticals recently announced new AURORA 1 Phase 3 analysis at the EULAR 2026 Congress, showing LUPKYNIS significantly reduced renal-related events or death in lupus nephritis patients. This data strengthens the clinical evidence for the drug but does not eliminate r", "url": "https://www.sahmcapital.com/news/content/how-new-lupkynis-renal-outcomes-data-could-impact-aurinia-pharmaceuticals-auph-investors-2026-06-19", "source_name": "Sahm", "published_at": "2026-06-19T04:41:17", "published_display": "19 Jun 2026 04:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Aurinia Pharmaceuticals Inc's (AUPH) shareholder structure, listing major shareholders and institutional holdings. It highlights top individual shareholders like Tang Capital Management, LLC and BlackRock, along with a classification ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-auph/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T08:38:51", "published_display": "18 Jun 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Aurinia Pharmaceuticals Inc (AUPH), detailing regional contributions. It shows that the United States accounts for 93.21% of its revenue, totaling $263.84 million, while Japan contributes 6.79% with $19.21 million. Information on reve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-auph/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:01", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Aurinia Pharmaceuticals Inc (AUPH) has an earnings forecast score of 7.43, ranking 291 out of 388 in its industry. Analysts have set an average price target of $17.00 for AUPH, with most supporting a \"Buy\" trend. The company's expected revenue for the next quarter is $79.70 milli", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-auph/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:10:01", "published_display": "17 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals (AUPH) Stock Could Be 4.6% Undervalued After New LUPKYNIS Phase 3 Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T08:28:54+00:00", "published_display": "17 Jun 2026 08:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxOMENrNGt6UDlBamgwMmZFUmJzMjRwZUo2YUhjd3ZmM0hHTXhKY3dtZFFkWVFPR2xjRHdlb1VfbDVucHhjaWhfU1cxNnVnUU5PZjZnZ3JLOVRkX28xbkZ6RWdDQ09YalVNVzZzR3RZWUtmNUh4Y0hJQXQ1V0loRkJaUVBCYl9SN0w1cjlSYi02N0FpcUNRcVVFQk1yal93ZWJwOWVwa1FYa0hFdEUtY1pZQzZUNjhRbjlDVmdxNnczZzB2Vk5naG9rRU1zUi01NHVoOWNNc3AySlJxRlFVZ1JxNDNqcmJrUU9lbVZBaTZOVUtHVEVzdXQwUVNCNDR6SEl6YXlDa1ZQTFk1d0pvaG1Da1JR?oc=5", "source_name": "ChartMill", "published_at": "2026-06-16T09:10:35+00:00", "published_display": "16 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals and Four More Stocks See Activist Action", "summary": "This article reports on recent activist actions disclosed to the SEC, specifically focusing on Aurinia Pharmaceuticals and four other companies. The information is derived from 13D filings, which are required when an entity acquires more than 5% ownership in a company's securitie", "url": "https://www.barrons.com/articles/activists-13ds-aurinia-pharmaceuticals-dell-victorias-secret-valaris-univertal-technical-institute-7ffc01fc", "source_name": "Barron's", "published_at": "2026-06-13T02:40:16", "published_display": "13 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSVBDS29OM0lWcG56d1NXNmxlU1ZIdnpyWFZENy1kYUI2S2lTZnJvTDhEVFFIdWRKOUFkR1lIUFctVGZCNVhuVU5kdUVyX0xHM0xnWkRsbzFiOGtBbHFCUHNBR0FSOHUwaHd2OTZSZmJMVWVLcFVhYjd2YldnakhWMFFTTzZDQ0ZFdUV1cFVKV3hHWU5DWWx6LTd0aWdxQ0VRTmNmU1ZHOA?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following New LUPKYNIS Kidney Outcomes Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T08:33:07+00:00", "published_display": "10 Jun 2026 08:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia (AUPH) director Jeffrey Bailey granted 23,931 stock options at $15.67", "summary": "Aurinia Pharmaceuticals Inc. director Jeffrey Allen Bailey was granted 23,931 stock options with an exercise price of $15.67 per share. These options are part of his compensation, will vest one year from the grant date, and are set to expire on June 4, 2036. This transaction refl", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-f268386fd5eb.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:10:26", "published_display": "08 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036", "summary": "Aurinia Pharmaceuticals director Kathleen Goetz was granted 23,931 Director Stock Options on June 4, 2026, as compensation. These options have an exercise price of $15.67 per share and will expire on June 4, 2036, vesting one year from the grant date. Following this award, her di", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-170e57b99845.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:10:26", "published_display": "08 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant", "summary": "Aurinia Pharmaceuticals Inc. (AUPH) director Tina Susan Nova was granted 23,931 stock options as compensation, which are exercisable at $15.67 per share and will vest one year from the grant date of June 4, 2026. The options are set to expire on June 4, 2036. This transaction is ", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-c6eb05895c51.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:10:26", "published_display": "08 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options", "summary": "Aurinia Pharmaceuticals Inc. director Craig A. Johnson was granted 23,931 stock options as part of his compensation, with an exercise price of $15.67 per share. These options are set to vest one year from the grant date and will expire on June 4, 2036. The Form 4 filing indicates", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-a295bae126e4.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:10:26", "published_display": "08 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Long Term Shareholder Returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million", "summary": "Aurinia Pharmaceuticals' (AUPH) CEO, Kevin Tang, indirectly purchased 814,606 common shares across several transactions between May 29, 2026, and June 2, 2026, totaling approximately $12.5 million. This significant acquisition, representing 6.66% of his total holdings, occurred j", "url": "https://www.fool.com/coverage/filings/2026/06/07/ceo-buys-auph-815k-shares-for-125-million/", "source_name": "The Motley Fool", "published_at": "2026-06-07T13:09:01", "published_display": "07 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sales, option exercise at AUPH (NASDAQ: AUPH) reported", "summary": "A recently filed Form 144 for Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) details proposed and recent transactions involving option exercises and sales of common stock. The filing indicates a planned sale of 9,593 shares connected to an option exercise dated June 5, 2026, and als", "url": "https://www.stocktitan.net/sec-filings/AUPH/144-aurinia-pharmaceuticals-inc-sec-filing-4e7068d357ef.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:10:17", "published_display": "05 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Health Care Stocks Whale Activity In Today's Session", "summary": "This article identifies significant \"whale activity\" in the options market for ten healthcare stocks, including Aurinia Pharmaceuticals (AUPH), UnitedHealth Group (UNH), and Eli Lilly and Co (LLY). It details specific bullish or bearish options trades, their expiration dates, str", "url": "https://www.benzinga.com/insights/options/26/06/53037272/10-health-care-stocks-whale-activity-in-todays-session", "source_name": "Benzinga", "published_at": "2026-06-05T17:10:17", "published_display": "05 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tang group discloses 10% Aurinia (AUPH) stake plus $15 put options", "summary": "Tang Capital Management and affiliated entities have amended their Schedule 13D filing, revealing a beneficial ownership of 10.0% in Aurinia Pharmaceuticals Inc., totaling 13,044,106 common shares as of June 3, 2026. The filing also discloses that the group holds put option contr", "url": "https://www.stocktitan.net/sec-filings/AUPH/schedule-13d-a-aurinia-pharmaceuticals-inc-amended-major-shareholder--fd78ca986430.html", "source_name": "Stock Titan", "published_at": "2026-06-04T23:08:43", "published_display": "04 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong shareholder support for Aurinia (NASDAQ: AUPH) board, auditor and say-on-pay", "summary": "Aurinia Pharmaceuticals Inc. shareholders demonstrated strong support for the company's leadership and compensation plan at its 2026 annual general meeting. All five director nominees were elected with significant majorities, ranging from 86.50% to 96.59% of votes. Additionally, ", "url": "https://www.stocktitan.net/sec-filings/AUPH/8-k-aurinia-pharmaceuticals-inc-reports-material-event-a3e53a2b6518.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:39:41", "published_display": "04 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUPH: 25,000-share option exercise filed; Keenan sold 25,000 on 06/02/2026", "summary": "A Form 144 filing for Aurinia Pharmaceuticals Inc. (AUPH) indicates a 25,000-share option exercise with a proposed sale on June 4, 2026, settled by cash. The filing also notes a previous sale by Gregory Keenan of 25,000 shares on June 2, 2026, for $54,100,000. These transactions ", "url": "https://www.stocktitan.net/sec-filings/AUPH/144-aurinia-pharmaceuticals-inc-sec-filing-28de1409b136.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:39:41", "published_display": "04 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow (NASDAQ:AUPH)", "summary": "Aurinia Pharmaceuticals (AUPH) is poised for profitable growth, buoyed by strong financial results from Lupkynis and strategic pipeline expansion through the Kezar Life Sciences acquisition. The company reported impressive 1Q26 figures, including double-digit revenue and net inco", "url": "https://seekingalpha.com/article/4911916-aurinia-cash-generating-today-pipeline-driven-tomorrow", "source_name": "Seeking Alpha", "published_at": "2026-06-04T12:39:41", "published_display": "04 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock", "summary": "A 10% shareholder of Aurinia Pharmaceuticals (AUPH.US) recently purchased 2,367,314 shares of common stock for a total of US$12.46 million. This transaction occurred at an average price of US$5.26 per share. Following this purchase, the shareholder now directly owns 20,449,602 sh", "url": "https://www.moomoo.com/news/post/70963167/aurinia-pharmaceuticals-auphus-10-shareholder-buys-us-12-46-million", "source_name": "Moomoo", "published_at": "2026-06-04T09:39:13", "published_display": "04 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals Insider Bought Shares Worth $12,455,227, According to a Recent SEC Filing", "summary": "This article reports on a significant insider purchase of Aurinia Pharmaceuticals shares. An insider acquired shares valued at $12,455,227, as disclosed in a recent SEC filing. This transaction could indicate insider confidence in the company's future prospects.", "url": "https://www.moomoo.com/news/post/70978343/aurinia-pharmaceuticals-insider-bought-shares-worth-12455227-according-to-a", "source_name": "Moomoo", "published_at": "2026-06-04T02:39:41", "published_display": "04 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.", "summary": "TANG CAPITAL MANAGEMENT, LLC has filed an early warning report concerning Aurinia Pharmaceuticals Inc. (AUPH). Quantisnow, a market data and news platform, provided this update, alerting its Plus members shortly after publication. The platform aggregates real-time information suc", "url": "https://www.quantisnow.com/insight/tang-capital-management-llc-files-early-warning-report-respecting-aurinia-6585548", "source_name": "Quantisnow", "published_at": "2026-06-03T23:10:26", "published_display": "03 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy", "summary": "Aurinia Pharmaceuticals' CEO, Kevin Tang, recently made a substantial insider purchase of 814,606 shares, totaling $12.46 million. This transaction signals insider confidence in the company, whose shares saw a 2.47% increase on Wednesday morning. The company demonstrated strong f", "url": "https://www.benzinga.com/insights/news/26/06/52974540/chief-executive-officer-of-aurinia-pharmaceuticals-makes-12-46m-buy", "source_name": "Benzinga", "published_at": "2026-06-03T15:10:27", "published_display": "03 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals stock (CA05156H1070): shares steady as Nasdaq-listed biotech advances myasth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQS2w1a1llS1lpQ0R2dVhSdTlYcGN2NzlYcG9vSEVrdGZDMW1JcUFGSTZiTzF2MTBPV1Nhcl9VOVdzNE90R3NZaThlYmVHUkc3LWd0UHdpLWtVdndvWTVaWnNyQXlFaENyc3hMcDAtb1Q4VTg3aG9mZDhTSFl3Q0J3emtfNmprWW9qWHlsTGprMWZMLWFQZE82T2c2Qmd6VHI2eDFVWk81eEFaY3lXWlljcjFGZzZQNWFVRUE?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options", "summary": "Entities linked to Aurinia Pharmaceuticals (AUPH) CEO Kevin Tang significantly increased their stake in the company by purchasing 814,606 common shares at around $15 per share. These funds now indirectly hold 13,044,106 shares. Additionally, Tang-affiliated funds sold 10,000 shor", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-7b1285a468b2.html", "source_name": "Stock Titan", "published_at": "2026-06-03T01:33:35", "published_display": "03 Jun 2026 01:33", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25,000-Share Sale Notice for AUPH (NASDAQ: AUPH)", "summary": "Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has filed a Form 144 notice for the proposed sale of 25,000 shares of common stock on June 2, 2026. This sale is tied to the exercise of options under a registered plan and will be an issuer-directed sale with cash proceeds. The filing ", "url": "https://www.stocktitan.net/sec-filings/AUPH/144-aurinia-pharmaceuticals-inc-sec-filing-590370bdd580.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:13:15", "published_display": "02 Jun 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals stock (CA05156H1070): shares steady on Nasdaq after Q1 2026 earnings beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUnJlUXNZQW55bzV1X3FaaEZkNEhpRUNocFFwY1lHRnIwUml6RnAwNGpNNEVJRVhpS2EwME84ZUliU1lrc2dXeFg2a2hGaWhfX1RJeWE4YTkwWkV2cWJkbjhGZEQtZlFoRERiV2RObF9PUTN4WmEzTjFvdFZoWHc0dGdGQ0RzNnBNaFlpQUhSbmw2cEc4TmhDaFJabDJ3bU1QS29Ta19lWnRkdGJyU09RanNYa28yQnRzeGFDQzlWc3hLM2c?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-01T19:32:33+00:00", "published_display": "01 Jun 2026 19:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in AUPH Response", "summary": "This article analyzes Aurinia Pharmaceuticals Inc (AUPH) using AI models, identifying divergent sentiment across different time horizons. It provides specific trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with entry zones, targets, and stop losses. The ", "url": "https://news.stocktradersdaily.com/news_release/101/Discipline_and_Rules-Based_Execution_in_AUPH_Response_052826053002_1780003802.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-28T17:10:45", "published_display": "28 May 2026 17:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments", "summary": "Aurinia Pharmaceuticals (AUPH) has maintained an analyst consensus target of $17.00, supported by updated model inputs and recent sector deal activity, though some analysts express caution regarding company-specific execution risks. The company recently appointed new executives a", "url": "https://simplywall.st/narratives/u6qzqcmm-auph-future-opportunities-will-depend-on-pipeline-clarity-and-risk-developments?bpId=4200549&link_type=cta_ai_narrative", "source_name": "Simply Wall Street", "published_at": "2026-05-27T20:09:10", "published_display": "27 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO", "summary": "Aurinia Pharmaceuticals (AUPH) has granted its Chief Financial Officer, Michael S. Hearne, 116,144 performance stock units (PSUs) and 70,230 employee stock options. The PSUs are performance-based, vesting in tranches upon the company's shares reaching specific target prices and t", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-7409ad983245.html", "source_name": "Stock Titan", "published_at": "2026-05-21T03:39:03", "published_display": "21 May 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options", "summary": "Aurinia Pharmaceuticals Inc.'s Chief Operating Officer, Ryan Cole, was granted 116,144 performance stock units (PSUs) and 70,230 stock options. These equity awards are compensation-related, with the PSUs vesting based on share-price targets and time-based conditions, and the stoc", "url": "https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-b5bce3850f27.html", "source_name": "Stock Titan", "published_at": "2026-05-20T21:09:21", "published_display": "20 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOMktqVFJ4TFZzV2NDeERPNWZwMkxycmhaamcxT3oyRWp4SUEwbmtqRkZCMU9lN3ZDajE4RXpfS0NuZzc0RFNPYms1OGhGM0FaaktVUzdSUjZUbEJValF3VlNCN2x1SDk1bFlEcDZNQnFBek1TM3Q0SmhPMkVFQnprLVNTREMtTkhvN3daQ0F2ZnUzY3k0ekhLNU93Nk1nMkg3cjRKVFdWcWZVWFlH?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals stock (CA05156H1070): Announces $6.955 Cash Acquisition of Kezar Life Scienc", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNSEFGSDh0cjVVWF91MnhSNVBXSjlPRVJtSWM4aVlld0gtX0ZtUS1Cbjc4RGxyaXQtQklOcVdVSXpOaWhSRk00ajZWRWRmSWQ2NXNJbWZIMENqZkJnQ25HaWwzMnlDbVE2U0ZSbm5nX1IyUUV3Rlp6U1A4dG01b3pHa0g2LUtCQ0VhQkRieTFvQVJxRWRqOE4yWkdoMVY5T3dwODVob1UtNVVOLTZueGJEcFZTTVk1aUI3VjNXWFB5Zw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kezar Life Sciences acquired by Aurinia Pharma U.S.; Nasdaq delisting follows", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPS0stcVVmbjh0UnJqbVp5X2tSQmJRd2gtSVh2cVNZMmk4amRYbkFNQTY0XzdBMkxiMktLMDBuUnpnU3R3MHBVVUVWcnkzNW5jbnNsVUVDeXZ0RDhDOTRYWm9WTjBVR2hNWjJOT0FkS1ZsYVBUVUN5aGlPLUQxQnVjSFRVTHFrd21Pa2ZmOHRPOXN0QWJJMDE1SkJma2g4aGFwbDBOQTR1OERwT0Fvd25pbnduc2lmaWpPNG55ZTk5bDBDZVpoMmJXNU5R?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "500,503 AUPH shares listed for resale by Morgan Stanley (NASDAQ: AUPH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOOGVqSGpxU2ZUTlZwelRoUWV3MURRYkZkWlJ5M1d3dDlZbHVGdzVzRnNHb3hQYkxLNmJ2WUhGNDAwREluWEZqb0h6YkNXWmxSNjhJZmdPX0NhMXFhWk5ha09IZzhUWEUyQ0hFSWF1TWVNaEpHVjBiazVsYnk4cjM4MFhHYzAtOFdTdmtmNkZCTUczTm9TQWJvVnh5bGdHWVhFZy1vekl1RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOc0RxM2VTc0ZtRHRUWnM2OGMwTWE4X1BUaFYtXzlzNEFtNGt3eklfUllQWmU4WlJyQXV0UTdobWZVZEtKcGY4b3FDWVZNZUVtZnBCZW5PSG1mUDdiSml4N0xHLVJsUnRPMEpoX0t4WEhPczlMeFdMN3NFVHZRNjdXRmdwVFByMTlqZzYyZDlEYVhYcllXUFhvZTdXTlFEY2RxeE9EM0RNMUIxOFVpSEE?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Screens Strong on Minervini Trend Template and High Growth Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNdVRfRW9xNEFoN0Zhd0NoYkF6RnlVbk1SZ0VvcDBuSTR4YlBMajkxUWJjMnp2aXd3eUhRMEhvUjNxTjVKWV9zZEk0TFRjdkhNRlp1VER5a0lkLVNPMUhqc3lSR09GZjludnFtd29GYndmMWJQMGEtdG1wNmhTQmpDeEZ3MXk0LUYwZDNhSW9CLTYwbXM5M1Q2dW45R0RCWFdMTGw1Y1lYcE5zb213S3Fsdmh1NFFrLVk2RG5RU1JGRkFwdUhvX3RSYXZVOUFCeFkyVk92RVVLaDE4YXktLVl6aWZNaXNPTzVvTHVhZ3lCdw?oc=5", "source_name": "ChartMill", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUPH (Aurinia) beats Q4 2025 EPS estimates by 17.6 percent, yet shares dip 1 percent in today\u2019s session.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOaTgwQjV4aVo4YzZabmNzVFp0ZV9kUDIwQldjVDQzTVcwZG5xZzAwekVJS2g0dGk3NWRROXNrckI3a0ItS3dJRmt3V0d1c2lqQlFRcVNGaEhkblU3bVdQOGVEU1VsUHE3V042RHlSS25JQXAxOUUxYWRDbk5zelJaLUJHZVY1TFBSSDVoOHFmdHkzS0xVSUhyeWhwREFmSlo3c2NIQzZCejYyWVF3UWJxbEhQRXo3YnFPd2N3a1lLTWFockpaYmJveVh1dHQxdURBNXducEc4UQ?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Aurinia Pharmaceuticals (AUPH) Pricing Reflect Long Term Value After 71% One Year Gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPMU04ellOeF9ZSWkwdVdwZEd5UTZwNDZhY1gyQVFESkN5eVlWMld0MFJJbF85ZTJaQUs4SGxvcTB1UXJVLTYwekp1RzhSVDE5aEZBRHVUb1VHTzBUcG50aEI1TjFlblhXUkZNZnlKQmF5YklQa09nUnFURFhKY0M1UHNkSHFEaGs0Qjc5UDg1WDFFMUFq?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUPH Stock Gains On Aurinia Pharma\u2019s Q4 Beat, But 2026 Guidance Misses Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQdmlya3JJeHF0TE1oT29lcDVZZzlndC0wZ19hU3NLVGtQWndqd0NzQmsxSUlUQlU3MGZiWDE0Rmx5WFNJYlRVMjI0UC1VSklURFlvVjBTRDRkVXB6ZFBIWm1JTUlXb3hJckV2bDFVOVcwMEpTbG14OUVPc2FCRjA0eG0zZ1k3OGs3Tm9BVnpxWjRUdHhMV0tBeU9nY1pyTVE4SllHSGhCMUs2N1BPelVFQUl6Zk01WkVybGdDS1B3RmFwcUZmQVhybTFVUUR1NFU?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 47, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief \u2014 Retail Traders Cry \u2018Stock Manipulation\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNZ0JFZFBCVElKc0w2LTd2VWJuMXk4YmN2aVU1TDBHUUxIOUNYU0U1ZmJiQUF6TjRoRUZvRm02aVVQaGt5Ti1IOHBtWWtzNUZ1SGlfSGFpbXVzSFVUNmxwMVBTUG1yVGM3QlRKVk9IODZ4eGFCR1pPMjdhMHlmel90XzEtanItSU5rNEJLeU1mQzZrZ25pODN4UnBQTGY1TF9Ha1QyLXdCcFFSbFRBS3h1aGU0QXZKekFvRzc4MU9fVnZUcmFna0Q5a21xNDhyQ3R6X2ZJOHBXSVlxRmY2MlE?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With 54% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNY2t1R0VQMlRGMjRUWjR0cEktd1dTcGtjSGpUaVRMd292NzR0QmJqTTQyMXRDVDhUUWRmT2IzWDBUbjdPT0poWXI3cmllWG1LS0pTdlVGQ2FuWS03azlRRnpmM2UyMGRMaUFUZWptbm9CdWRFTk9leG85VzR4ckdtb2VMODFyaTBOT2pWWjUwTkJRa0sxeDVlSnBhWlQ?oc=5", "source_name": "Market source", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOVZ0MTZsNmg4eGN5d1dOdk84Tk54NlE0bzdFaWhVZHFiSWNvX1ZBY1JFWWJUREpXSFlYb2Q1S1VkYmQzdDVSRjdFZTZpTUpFdzFtelZwZk53bFhsSmhmNDlweWZkUVpvczNYQkpDR0RpQWFEQnVOVE1LU3dMLVl0a055ZDBQTTZUQ0tjOGs3T3hqXy1DdklBblFFdGhyMWFlMzg0LU1RMGY?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-08T08:00:00+00:00", "published_display": "08 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNeEtmMFI0aDZ3MS1STFpyZzVtZzlHWEhacF9IdEE4ZVZOOXlnbHBLSWV3WjVzRnA1MjVWQjFzRERIY29QaGdlVlVaOXBvT1lmbWlIZnd2d19qVXdmeGcwZlplWDJ4REZ2S3hUX0VfaVBsNlBQOW9KOUJteTZLbFljRC1VZmdDN2pUWExlanUyRjhuVEwtQ3AwWV84dDdHUXB1bVFvLXU1ZDJxMU5PTG9QMk9KWDNtdEZhSEM2aTI3Z2RiY2FJYWJZM0l2bHhHazRQcnJMX1hvVGFKUWQ4bi1qTGxNVHZZd1nSAewBQVVfeXFMTm1HOFFxSGR3TUhXTDAtQjFvN2VPMkI4dU1JWXYxMDVNYm5kX1ZLSFpwWmdWbl9aaW5FdEhZNnNYbmFNM1pXTVRxVUI0cFlhcmp0ME1MRFRxV2FadGtXZ0tSX0ZfTjZ0dEdYMEptU3hJUmtycEJ3TTdGV3NjRDllcmZBLXNUX2p2MDVEY21wQXExdkNUVWxrc0c4Rkg5NVlhY0hhWmVmQ0VhWFJDS2NGbE9GT0IyYUZRckRJblRMTkxoN1RkaDBTaVN6T2tNbC1IQUlubHc4bjkzekNMWGNtZjRpd3hQSDFTYlRUZUk?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 56, "sentiment_summary": {"positive": 21, "negative": 3, "neutral": 32, "score": 58, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.65, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 6.74, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 3.1, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 16.46, "latest_week": "2026-06-19", "one_week_move": 4.0, "four_week_move": 8.1, "twelve_week_move": 15.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.357657, "market_dynamics_buy_signal": false, "relative_strength": -0.078069, "fair_value_gap": 70.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.3402, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.0% over one week, +8.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 10}, {"label": "simplywall.st", "count": 8}, {"label": "TradingKey", "count": 3}, {"label": "AD HOC NEWS", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "ChartMill", "count": 2}, {"label": "Benzinga", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 5}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+4.0% over one week, +8.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Understanding Momentum Shifts in (AUPH)"}], "updated_at": "2026-06-22T18:11:38.882890+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}